ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Wound Biofilm in Acute and Chronic Wounds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00764348
Recruitment Status : Withdrawn (withdrawn as MSU approval obained)
First Posted : October 2, 2008
Last Update Posted : September 7, 2011
Sponsor:
Information provided by (Responsible Party):
Randall Wolcott, Southwest Regional Wound Care Center

Brief Summary:
Patients who present to a wound care center for management of their wounds will be evaluated clinically to establish if their wounds are chronic or acute. These patients will undergo standard of care management of their wounds. If debridement is indicated for the patient, the patient will be asked to participate in a study. Once the standard of care debridement is complete, the material debrided from the wound, instead of being discarded into a biohazard bag, will be prepared for shipment. The samples will then be shipped to the Center for Biofilm Engineering where microscopic evaluation will be conducted on the material. Conclusion will be made from that analysis.

Condition or disease Intervention/treatment
Wounds Other: no treatment

Detailed Description:
A planktonic concept of the bacteria present on the surface of a chronic wound is no longer viable. Microscopic studies show that biofilm is present on chronic wounds yet does not seem to be prominent on the surface of acute wounds. Biofilm is able to neutralize our host defenses and commandeer host systems, and possesses an impressive array of defenses and virulence factors. Clinically we see a significant difference in the healing behavior between chronic and acute wounds. Also, suppression of biofilm using multiple simultaneous strategies including debridement, anti-biofilm agents, specific biocides, antibiotics and advanced technologies improves wound healing. This suggests biofilm plays an important role in delayed wound healing.

Study Type : Observational
Actual Enrollment : 0 participants
Time Perspective: Prospective
Official Title: Evaluation of Wound Biofilm in Acute and Chronic Wounds

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
no treatment Other: no treatment



Primary Outcome Measures :
  1. It is important for all wound care providers to firmly grasp the wound biofilm concept, its importance in delayed wound healing, and how it differs from a planktonic bacterial concept.

Biospecimen Retention:   Samples With DNA
traumatic, diabetic foot ulcer, decubitus ulcer, venous leg ulcer


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Acute and Chronic Wounds

Responsible Party: Randall Wolcott, Prinicipal Investigator, Southwest Regional Wound Care Center
ClinicalTrials.gov Identifier: NCT00764348     History of Changes
Other Study ID Numbers: 56-RW-002
First Posted: October 2, 2008    Key Record Dates
Last Update Posted: September 7, 2011
Last Verified: September 2011

Keywords provided by Randall Wolcott, Southwest Regional Wound Care Center:
Acute and Chronic Wounds

Additional relevant MeSH terms:
Wounds and Injuries